Fundamental Analysis of MACROGENICS INC(NASDAQ:MGNX) stock

Fundamental Rating

Overall MGNX gets a fundamental rating of 3 out of 10. We evaluated MGNX against 565 industry peers in the Biotechnology industry. While MGNX seems to be doing ok healthwise, there are quite some concerns on its profitability. MGNX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

MGNX had negative earnings in the past year.

MGNX had a negative operating cash flow in the past year.

MGNX had negative earnings in each of the past 5 years.

MGNX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

MGNX has a Return On Assets of -36.91%. This is in the better half of the industry: MGNX outperforms 60.61% of its industry peers.

Looking at the Return On Equity, with a value of -81.30%, MGNX is in line with its industry, outperforming 50.80% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-36.91%
ROE	-81.3%
ROIC	N/A

ROA(3y)-35.35%

ROA(5y)-37.77%

ROE(3y)-58.22%

ROE(5y)-56.86%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MGNX has a better Gross Margin (95.07%) than 95.37% of its industry peers.

The Profit Margin and Operating Margin are not available for MGNX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	95.07%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for MGNX has been increased compared to 1 year ago.

MGNX has more shares outstanding than it did 5 years ago.

There is no outstanding debt for MGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -5.32, we must say that MGNX is in the distress zone and has some risk of bankruptcy.

MGNX's Altman-Z score of -5.32 is on the low side compared to the rest of the industry. MGNX is outperformed by 62.21% of its industry peers.

MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.32

ROIC/WACCN/A

WACC10.41%

2.3 Liquidity

A Current Ratio of 3.75 indicates that MGNX has no problem at all paying its short term obligations.

The Current ratio of MGNX (3.75) is comparable to the rest of the industry.

A Quick Ratio of 3.69 indicates that MGNX has no problem at all paying its short term obligations.

MGNX has a Quick ratio (3.69) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.75
Quick Ratio	3.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for MGNX have decreased strongly by -95.06% in the last year.

MGNX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.70%.

The Revenue has been decreasing by -0.45% on average over the past years.

EPS 1Y (TTM)-95.06%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%221.43%

Revenue 1Y (TTM)16.7%

Revenue growth 3Y-17.57%

Revenue growth 5Y-0.45%

Sales Q2Q%964.81%

3.2 Future

The Earnings Per Share is expected to grow by 2.58% on average over the next years.

The Revenue is expected to grow by 14.97% on average over the next years. This is quite good.

EPS Next Y20.33%

EPS Next 2Y-14.23%

EPS Next 3Y-6.77%

EPS Next 5Y2.58%

Revenue Next Year57.92%

Revenue Next 2Y4.88%

Revenue Next 3Y5.03%

Revenue Next 5Y14.97%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGNX. In the last year negative earnings were reported.

Also next year MGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as MGNX's earnings are expected to decrease with -6.77% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-14.23%

EPS Next 3Y-6.77%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MGNX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MACROGENICS INC

NASDAQ:MGNX (11/21/2024, 8:00:01 PM)

After market: 3.39 +0.18 (+5.61%)

3.21

-0.07 (-2.13%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap201.46M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-36.91%
ROE	-81.3%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	95.07%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.53

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.75
Quick Ratio	3.69
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-95.06%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y20.33%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)16.7%

Revenue growth 3Y-17.57%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

MACROGENICS INC (MGNX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens